HOME › Research Insight › Radiopharmaceuticals Market - Global Trends & Forecast to 2017
Radiopharmaceuticals Market - Global Trends & Forecast to 2017
The global nuclear medicines market was majorly dominated by Tc-99m (SPECT radioisotopes), F-18 (PET radioisotopes), and I-131 (beta therapy isotopes) in 2012. Tc-99m is considered as the gold standard in the diagnostics market and hence ensured a stable market due to its high popularity. Despite its market maturity, ongoing clinical trials have found novel diagnostic applications for Tc-99m. Tc-99m exhibited satisfactory clinical efficiencies in the diagnosis of breast cancer and coronary heart disease. Besides Tc-99m, Tl-201 is considered the most potential isotope in the SPECT diagnostic market owing to its usefulness in the diagnosis of coronary artery disease.
The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimers disease are the most promising indications for the future PET radioisotopes market.
Therapeutic segment leader-I-131-has found its new clinical applications in the ongoing clinical trials. Lymphoma is one of the most notable indications amongst all others. Y-90 and Lu-177 have been considered as the highest-growing isotopes markets owing to their emerging popularity in lymphoma, hepatocellular carcinoma, and neuroendocrine therapeutic procedures. Besides beta therapy isotopes, huge market potential lies in the upcoming alpha therapy market. Alpharadin (Ra-223) is expected to be the leading isotope in this therapeutic segment. Though Alpharadin is not marketed yet, its excellent clinical outcome in bone metastases and prostate cancer treatment has earned significant attention among radiopharmacists and oncologists.
The U.S. market, supported by the Mo-99 production of NRU reactor, held the maximum share in the global radiopharmaceuticals market. Ongoing research in different institutes such as National Cancer Institute and Avid Radiopharmaceuticals also influence the radioisotopes market with interesting clinical studies such as the significant potential of Alpharadin molecules. Thus, North America still presents potential opportunities for future growth. Lucrative markets in the European region include Germany, France, and the U.K. Besides the developed markets, emerging countries such as China, India, Japan, South Korea, Brazil, and South Africa also represent significant growth opportunities driven by government initiatives as well as the increase in production by local reactors.
Related Reports @
Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017
North - Dominion Plaza,
Suite 800, Dallas, TX 75252